Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CEDI (Clinical Enzyme Diagnostics) was a specialized diagnostic laboratory and spin-off from the Academic Medical Center (AMC) in Amsterdam, Netherlands. The company focused on the biochemical diagnosis and monitoring of lysosomal storage diseases (LSDs), gaining international recognition for its expertise in enzymatic assays and biomarker development. CEDI is particularly known for its pioneering work on chitotriosidase and Lyso-Gb1 as critical biomarkers for Gaucher disease. In 2016, the company's assets and specialized expertise were acquired by Centogene, a global leader in genetic diagnostics, to enhance their biochemical testing portfolio for rare diseases.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CEDI Diagnostics.